Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

Excessive scalp sebum, worsened by DHT, can lead to inflammation and hair loss, with clascoterone mentioned as a treatment. Diet changes seem ineffective for scalp sebum, and treatments like minoxidil and finasteride are suggested.

User took 0.5mg Finasteride daily and 1x Minoxidil daily for 3 months, experienced positive hair growth and temporary side effects. Recommends sticking with treatment and adjusting dosage if needed.

A 26-year-old male experienced hair regrowth using finasteride, minoxidil foam, and micro-needling over 2-3 months, with significant improvement in the crown, sides, and temples, but less in the hairline. He noted side effects like fluid retention in the ankles and weight gain but no change in libido.

The user started using 1mg finasteride and Regaine foam post-hair transplant, noticing significant hair growth at three months. They experienced testicular cramps as a side effect but no other issues, and are considering microneedling for further improvement.

A user is concerned about hair thinning at 23 and is considering Minoxidil and finasteride for treatment, asking about long-term use and side effects. They also mention using collagen and exploring acupuncture for hair regrowth.

The conversation discusses a 4-month hair regrowth protocol that includes finasteride (1.25mg), RU58841, dermarolling, ketoconazole, minoxidil, peppermint oil, and fatty acids/oils. Progress pictures are shared to show the results of these treatments.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

Low-level laser therapy (LLLT) is debated for hair regrowth, with some users suggesting it should be combined with treatments like minoxidil and finasteride for effectiveness. Many users express skepticism about LLLT's efficacy and cost, emphasizing the need for the correct wavelength and quality devices.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly credits a person for the potential success of a treatment called GT20029.

The user has been using Minoxidil 5% since August and has noticed hair regrowth, with the left temple showing more concentrated growth and the right side having scattered single hairs. Some hairs are turning black, but the right side doesn't yet appear as full as the left.

The user reported tiny hair growth in thinning areas and improved thickness after 56 days of using 1 mg oral finasteride, 2.5 mg oral minoxidil, and a serum with Redensyl, Anagain, Capixyl, and Procapil. They also take supplements and maintain a healthy lifestyle with no noticeable side effects.

The user is pleased with hair regrowth after taking daily tablets of 1.1 mg finasteride, 3 mg minoxidil, and 2.5 mg biotin for 3 months, with no side effects and some light shedding. The most noticeable improvement is at the crown, which was the main concern.

PP405 may induce new hair growth but cannot revive completely dead follicles, and its effectiveness on hairlines is uncertain. It is expected to be available by mid-2028, but users are advised to manage expectations and consider using other treatments like minoxidil and finasteride.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

Breezula's effectiveness is uncertain, with some users skeptical about its potential and others noting its recent availability on the grey market. A user reported success with a stack of Dutasteride (oral), Minoxidil (topical), and RU58841 (topical), achieving significant hair improvement after 18 months.

The user has been using a topical solution of minoxidil and finasteride for one month, experiencing some hair shedding. They also use a multivitamin, derma rolling, and a shampoo with ketoconazole and salicylic acid, seeking advice on additional treatments.

The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.

GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.

A 39-year-old has been using topical 5% minoxidil for 11 years, added microneedling, and recently started using a topical combination of minoxidil and 0.3% finasteride, noticing some hair regrowth after three months. They experienced minor side effects when switching finasteride concentrations and plan to continue the treatment, possibly adding oral finasteride or dutasteride if significant progress is seen after a year.

3 months of progress with Finasteride and Minoxidil treatment for hair loss, as well as Nutrafol vitamins and low-level light therapy. The user experienced no problems and had a satisfied girlfriend to boot!

A stem cell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.

A user has been using 1mg oral finasteride and 5% topical minoxidil for six months, with some derma stamping, but feels hair growth has stagnated and is considering PRP or a hair transplant. Others advise continuing the current regimen, noting that maintaining existing hair is an achievement, and suggest ignoring negative comments from friends.

The conversation is about creating a topical hair loss treatment with B6, zinc, and azelaic acid, which is claimed to inhibit 90% of scalp DHT. One user is skeptical about the effectiveness of this treatment and its comparison to other treatments without side effects.

The conversation is about the potential impact of RU58841 on male fertility, specifically regarding sperm concentration, total count, and motility. The user is curious about the likelihood of RU58841 reducing fertility based on its mechanism of action and comparisons to similar substances.

RU58841 is discussed as a hair loss treatment, with users considering lower doses like 2.5% to reduce costs. Some users suggest that if already blocking DHT, lower doses might still be effective unless there's high sensitivity to DHT.

A user reported significant hair regrowth after 3 months using 1mg oral finasteride, 1ml 5% topical minoxidil, and microneedling, along with biotin, vitamin D, iron, and zinc supplements. They are optimistic about continued progress despite initial skepticism.

The conversation discusses various hair loss treatments, including Minoxidil, finasteride, tretinoin, latanoprost, and GHK-Cu, with skepticism about expensive branded products like Zeus. Users suggest that similar results can be achieved with cheaper alternatives.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.